Mike Masnick at Techdirt shreds The New York Times’ breathless puffpiece on telehealth startup Medvi:

It’s a hell of a story. The problem is that almost none of it holds up to even the most basic scrutiny, and the fact that the New York Times — the New York Times — fell for it (or worse, didn’t care) is an embarrassment. As much as I’ve made fun of the NYT for its bad reporting over the years, this is (by far) the worst I’ve seen. They didn’t just misunderstand something, or try to push a misleading narrative, they got fully played on a bullshit story that any competent reporter or editor should have realized from the jump. This one stinks from top to bottom.

AI, misleading valuations, fake doctors, class-action lawsuits, an FDA investigation, and false weight-loss claims. It appears the writer, Erin Griffith, and Times editors and fact-checkers did zero actual reporting for this story.

The real issue now is what the New York Times plans to do about this. A standard correction noting a few missing details won’t cut it. The entire premise of the article — that this company represents the exciting realization of AI’s business potential — is nonsense. Every element of the narrative is tainted: the growth story is built on deceptive marketing, the product claims are contradicted by the FDA and the manufacturers of the actual drugs, the “$1.8 billion” figure is a projection with no valuation to back it up, and the company is currently facing legal action on multiple fronts. The entire article should be retracted.

A week later and the Times has yet to issue a correction or retraction.